科學+家 螯合研究 | SCIENTIST HOME Chelation Study
螯合研究
關注:
- 血管組織
- 重金屬和鈣化
- 疼痛和麻木
- B-澱粉樣蛋白
- 膽腎的鈣和鐵
- 纖維化
- 膽固醇和血壓
- "黑"腳
__
螯合療法
暴露於環境和職業毒物對人類健康造成不利影響。螯合療法是唯一能够去除人體器官和組織中有毒金屬的方法,旨在治療與急性和/或慢性中毒有關的損害。本文綜述了螯合劑乙二胺四乙酸(EDTA)成功應用的最新證據。乙二胺四乙酸(EDTA)對急性和慢性毒性金屬負荷的治療,以及其它毒性金屬螯合劑和鐵螯合劑的臨床意義。
有毒金屬: 鋁、銻、砷、鋇、鈹、鉍、鎘、銫、釓、鉛、汞、鎳、鈀、鉑、碲、鉈、釷、錫、鈦、鎢、鈾
環境污染對金屬攝入量的影響
有毒金屬會對人體健康造成許多不良影響。個人可能通過多種途徑接觸環境中存在的有毒金屬,例如通過吸入空氣污染進入呼吸道 [1],或通過攝入受污染的食物和水進入口腔[2]。環境暴露對一般人群來說是一種健康風險,更具體地說,對某些專業類別來說是一種健康風險。
- 高風險工人
- 與地理區域相關的毒性
- 對懷孕和兒童的影響
- 對器官和系統的影響
- 對細胞的影響
考慮到有毒金屬暴露對人體健康造成的嚴重損害,我們應該研究如何在人體內確定這種污染? 每種有毒金屬的靶器官、來源和毒性水平: 腎臟、中樞神經系統、肝臟、胃腸系統、呼吸系統、皮膚、心血管/造血系統、口腔/鼻粘膜、肌肉骨骼系統。
鈣化:
鈣化是指鈣沉積到血管的新內膜(動脈粥樣硬化斑塊內)和/或中膜(中層平滑肌層)中,可與動脈粥樣硬化、慢性腎病和糖尿病等疾病發生。血管鈣化導致血管硬化,影響動脈粥樣硬化斑塊的穩定性。
科學+家 螯合研究
可能適合多學科復康調理:
- 關節鈣化 1,2,3,4
- 骨刺(骨質增生)5,6,7,8(膝蓋、髖關節、肩膀、腰椎、頸椎、指關節…等)
- 血壓、膽固醇 9,10
- 全身血管、動脈彈性 9,10,11,12
- 身體組織鈣化(硬化)13,14
- 重金屬積聚 15-33
食用建議:在需要的時期,空腹食用由2至4粒,每日3次;兩餐中間或飯前1小時前食用。
注意:
- 本品為營養補充品,不能代替藥物。
- 如有不適反應,建議停止服用。
- 妊娠期和哺乳期婦女慎用。
- 如不瞭解問題原因或問題持續,請儘快諮詢醫生。
- 有身體過敏、心臟或腎衰竭患者、癲癇症,不要食用本品。
主要成份:奧谷胱甘肽、麩氨基硫、乙二胺四乙酸鈣2鈉、磯醇已磷酸、植酸、肌醇六磷酸酯、不旋光肌醇、環己六醇六磷酸。
規格型號:300毫克/80粒/腸溶膠囊
份量:10-20天
儲存:請存放於陰涼乾爽處,避免陽光照射。
安全:乙二胺四乙酸鈣二鈉被美國食品和藥物管理局(FDA)準予用於螯合療法,它能從體內去除重金屬。據馬里蘭大學醫學中心稱,與乙二胺四乙酸鈣二鈉螯合的副作用包括吸收不良或低水準的各種維他命,包括維他命C和各種B族維他命。為了幫助對抗低維他命水准,乙二胺四乙酸鈣二鈉通常是與維他命同日分開食用。其他副作用包括過敏反應、危險的低血糖、血壓或血鈣水准、腎衰竭和癲癇發作。
副作用:如果你覺得你可能暈倒,或嚴重的水泡,剝皮,或紅色皮疹,請停止服用此產品,並告訴您的醫生,您食用過乙二胺四乙酸鈣二鈉。較輕的副作用包括:噁心、嘔吐、腹瀉、麻木或刺痛(尤其是口腔周圍)、頭痛、疼痛、發紅或針刺。
風險:乙二胺四乙酸鈣二鈉在處方藥、眼藥水和食品防腐劑中的小劑量是安全的。然而,有可能導致抽筋,噁心,嘔吐,腹瀉,頭痛,低血壓,皮膚過敏和發燒。每天食用超過3克是不安全的。太多會導致腎臟損害,低鈣水准,甚至死亡。
原產地:中國香港
如你有任何疾病, 請遵照閣下醫生的完整醫療方案; 而是否使用多學科復康方案前, 你必須咨詢主診醫生的意見, 如果閣下的主診醫生不建議您加入補充劑調理組合, 請你不要使用。如果你需要尋求其他醫生作第二咨詢, 閣下可聯絡我們線上<無邊界醫生>或你自己城市內的其他專業醫生的再診斷。
__
Chelation Study
Focus on:
- Vascular tissues
- Heavy metal & calcification
- Pain & numbness
- Amyloid B-protein
- Calcium & iron in gallbladder & kidney
- Fibrosis
- Cholesterol & blood pressure
- 'Black' foot
__
Chelation Therapy
Exposure to environmental and occupational poisons has adverse effects on human health. Chelation therapy is the only way to remove toxic metals from human organs and tissues, and is designed to treat damage associated with acute and/or chronic poisoning.
This paper reviews the latest evidence of the successful application of EDTA. The therapeutic effect of ethylene diamine tetraacetic acid (EDTA) on acute and chronic toxic metal load, and the clinical significance of other toxic metal chelators and iron chelators.
Toxic metals: aluminum, antimony, arsenic, barium, beryllium, bismuth, cadmium, cesium, gadolinium, lead, mercury, nickel, palladium, platinum, tellurium, thallium, thorium, tin, titanium, tungsten and uranium.
Effect of environmental pollution on metal intake: Toxic metals can cause many adverse effects on human health. Individuals may be exposed to toxic metals in the environment through a variety of ways, such as inhalation of air pollution into the respiratory tract [1], or ingestion of contaminated food and water into the mouth [2]. Environmental exposure is a health risk for the general population and, more specifically, for some professional categories.
- High risk workers
- Toxicity related to geographical area
- Impact on pregnancy and children
- Effects on organs and systems
- Effects on cells
Considering the serious damage to human health caused by toxic metal exposure, should we study the impact of these types of pollution on human systems?
Target organs, sources and toxicity levels of each toxic metal: kidney, central nervous system, liver, gastrointestinal system, respiratory system, skin, cardiovascular / hematopoietic system, oral / nasal mucosa, musculoskeletal system.
Calcification:
Calcification refers to the deposition of calcium into the neointima (atherosclerotic plaque) and/or media (middle smooth muscle layer) of blood vessels, which can be associated with atherosclerosis, chronic kidney disease, diabetes and other diseases. Vascular calcification leads to arteriosclerosis and affects the stability of atherosclerotic plaque.
SCIENTIST HOME CHELATION STUDY
Suggested multidisciplinary rehabilitation:
- Joint calcification 1,2,3,4,
- Hyperosteogeny (spur) 5,6,7,8 (knee, hip, shoulder, lumbar spine, cervical spine, finger joint, etc.)
- Blood pressure, cholesterol 9,10
- Systemic vascular and arterial elasticity 9,10,11,12
- Calcification (sclerosis) of body tissues 13,14
- Heavy metal accumulation 15-33
Consumption: When necessary, take 2 to 4 capsules each time, 2 times a day to be taken in between meals, or 1 hour before meal.
Caution:
- This product is a nutritional supplement and cannot replace medicine.
- Not suitable if:
- Pregnant or lactating.
- Children under 18 years of age.
- Enduring allergic reaction, kidney problem or epilepsy.
- Having heart or kidney failure.
- If discomfort occurs, please stop taking.
- If you do not understand the cause of your health condition or the issue persists, please consult your doctor as soon as possible.
Main ingredients: Oxiglutatione, GSSG, EDTA Ca Na2, Sauredesphytins, Phytic Acid, Phyticacidsolution, Dambose, Cyclohexanehexyl Hexaphosphate.
Specification: 300mg per capsule (enteric coated), 80 capsules per bottle.
Serving size: 10 to 20 days
Storage: Store in a cool and dry place, away from sunlight.
Origin: Hong Kong, China
Safety:
EDTA calcium disodium has been approved by the food and Drug Administration (FDA) for chelation therapy, which can remove heavy metals from the body. According to the University of Maryland Medical Center, side effects of chelating with calcium disodium EDTA include malabsorption or low levels of various vitamins, including vitamin C and various B vitamins. To help fight low vitamin levels, calcium disodium EDTA is usually taken separately from vitamins on the same day. Other side effects include allergic reactions, dangerous hypoglycemia, blood pressure or calcium levels, renal failure, and seizures.
Side effects:
If you feel you may faint, or have severe blisters, peeling, or red rashes, please stop taking this product and tell your doctor that you have taken calcium disodium EDTA. Mild side effects include nausea, vomiting, diarrhea, numbness or tingling (especially around the mouth), headache, pain, redness or needling.
Risks:
EDTA calcium disodium is safe in small doses in prescription drugs, eye drops and food preservatives. However, it can cause cramps, nausea, vomiting, diarrhea, headache, hypotension, skin allergy and fever. It's not safe to eat more than 3 grams a day. Too much can lead to kidney damage, low calcium levels, and even death.
If you have a medical condition, please follow your doctor's medical treatment plan. Do consult your medical doctor before using the Multidisciplinary Rehabilitation Program (MRP). Please do not proceed if your medical doctor does not recommend the use of our MRP. If you'd like to seek a second opinion from other doctors, you may contact our online "Doctors Without Border", or other professional doctors at your convenience.
__
參考研究報告 / Ref:
1. Grases F, Perelló J, Prieto RM, Simonet BM, Torres JJ (2004). Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. Life Sci. 75(1):11-9.1.
2. Grases F, Prieto RM, Simonet BM, March JG (2000). Phytate prevents tissue calcifications in female rats. Biofactors. 11(3):171-7.
3. Grases F, Perelló J, Isern B, Prieto RM (2005). Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br J Dermatol. 152(5):1022-5.
4. Grases F, Isern B, Perelló J, Sanchis P, Prieto RM (2005). Absorption of myo-inositol hexakisphosphate (InsP6) through the skin: study of the matrix effects mechanism of phytate topical absorption. Front Biosci. 10:799-802.
5. Sun Y, Mauerhan DR, Honeycutt PR, Kneisl JS, Norton HJ, Zinchenko N, Hanley EN Jr, Gruber HE (2010). Calcium deposition in osteoarthritic meniscus and meniscal cell culture. 12(2):R56.
6. Fuerst M, Bertrand J, Lammers L, Dreier R, Echtermeyer F, Nitschke Y, Rutsch F, Schäfer FK, Niggemeyer O, Steinhagen J, Lohmann CH, Pap T, Rüther W (2009). Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum. 60(9):2694-703.
7. Liu YZ, Jackson AP, Cosgrove SD (2009). Contribution of calcium-containing crytals to cartilage degradtion and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage. 17(10):1333-40.
8. Jaovisidha K, Rosenthal AK (2002). Calcium crystals in osteoarthritis. Curr Opin Rheumatol. 14(3):298-302.
9. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996; 10:78-86.
10. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990; 82:173-174.
11. Anderson HC1, Mechanisms of pathologic calcification. Rheumatic Diseases Clinics of North America, 01 Aug 1988, 14(2):303-319. PMID: 2845491
12. Andrew L Durham, Mei Y Speer, Marta Scatena, Cecilia M Giachelli, Catherine M Shanahan Author Notes. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovascular Research, Volume 114, Issue 4, 15 March 2018, Pages 590–600, https://doi.org/10.1093/cvr/cvy010. Published:05 March 2018
13. Anderson HC1, Mechanisms of pathologic calcification. Rheumatic Diseases Clinics of North America, 01 Aug 1988, 14(2):303-319. PMID: 2845491
14. Andrew L Durham, Mei Y Speer, Marta Scatena, Cecilia M Giachelli, Catherine M Shanahan Author Notes. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovascular Research, Volume 114, Issue 4, 15 March 2018, Pages 590–600, https://doi.org/10.1093/cvr/cvy010. Published:05 March 2018
15. Ferner DJ. Toxicity, heavy metals. eMed J. 2001;2(5):1.
16. Monisha Jaishankar, Tenzin Tseten, Naresh Anbalagan, Blessy B. Mathew, and Krishnamurthy N. Beeregowda. Toxicity, mechanism and health effects of some heavy metals. Interdiscip Toxicol. 2014 Jun; 7(2): 60–72. Published online 2014 Nov 15. doi: 10.2478/intox-2014-0009.PMCID: PMC4427717. PMID: 26109881
17. Brochin R, Leone S, Phillips D, Shepard N, Zisa D, Angerio A. The cellular effect of lead poisoning and its clinical picture. GUJHS. 2008;5(2):1–8.
18. Morais S, Costa FG, Pereira ML. Heavy metals and human health. In: Oosthuizen J, editor. Environmental health – emerging issues and practice. 2012. pp. 227–246.
19. Martin S, Griswold W. Human health effects of heavy metals. Environmental Science and Technology Briefs for Citizens. 2009;(15):1–6.
20. Martin S, Griswold W. Human health effects of heavy metals. Environmental Science and Technology Briefs for Citizens. 2009;(15):1–6.
21. Ailing bones and failing kidneys: a case of chronic cadmium toxicity. Chakraborty S, Dutta AR, Sural S, Gupta D, Sen S Ann Clin Biochem. 2013 Sep; 50(Pt 5):492-5.
22. Cadmium & its adverse effects on human health. Bernard A Indian J Med Res. 2008 Oct; 128(4):557-64.
23. Martin S, Griswold W. Human health effects of heavy metals. Environmental Science and Technology Briefs for Citizens. 2009;(15):1–6.
24. STUDIES ON CHROMATED ERYTHROCYTES. MECHANISMS OF CHROMATE INHIBITION OF GLUTATHIONE REDUCTASE. KOUTRAS GA, SCHNEIDER AS, HATTORI M, VALENTINE WN Br J Haematol. 1965 May; 11():360-9.
25. Acute fatal bichromate poisoning]. Schlatter C, Kissling UBeitr Gerichtl Med. 1973; 30():382-8.
26. Effects of glutathione on chromium-induced DNA crosslinking and DNA polymerase arrest. O'Brien T, Xu J, Patierno SRMol Cell Biochem. 2001 Jun; 222(1-2):173-82.
27. Matsumoto ST, Mantovani MS, Malaguttii MIA, Dias AL, Fonseca IC, Marin-Morales MA. Genotoxicity and mutagenicity of water contaminated with tannery effluents, as evaluated by the micronucleus test and comet assay using the fish Oreochromis niloticus and chromosome aberrations in onion root-tips. Genet Mol Biol. 2006;29(1):148–158.
28. Clayton DB. Water pollution at Lowermoore North Cornwall: Report of the Lowermoore incident health advisory committee; Truro: Cornwall District Health Authority; 1989. p. 22.
29. Krewski et al., 2009
30. Aluminium toxicity: its relationship with bone and iron metabolism. Cannata Andía JB Nephrol Dial Transplant. 1996; 11 Suppl 3():69-73.
31. Iron augments stage-I and stage-II tumor promotion in murine skin. Bhasin G, Kauser H, Athar M Cancer Lett. 2002 Sep 26; 183(2):113-22.
32. Iron, free radicals, and oxidative injury. McCord JM Semin Hematol. 1998 Jan; 35(1):5-12.
33. Pathophysiology of iron overload. Hershko C, Link G, Cabantchik I Ann N Y Acad Sci. 1998 Jun 30; 850():191-201.
__
本品等並非根據《藥劑業及毒藥條例》或《中醫藥條例》注册。任何對其提出的宣稱均不受此類登記評估的約束。本產品不用於診斷、治療或預防任何疾病。
This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.